Page 55 - 2021 Taiwan Food and Drug Administration Annual Report
P. 55
production equipment is shown in Figure Figure 4-2 and the production capacity will
4-1. The research and development of EH LQFUHDVHG WR VX൶FLHQWO\ PHHW WKH QHHGV RI
oxycodone hydrochloride immediate release domestic medical institutions.
FDSVXOHV PRUSKLQH VXOIDWH SURORQJHG UHOHDVH
capsules and matrix-type patches and the Section 3
planning of the production area of oral liquid
preparations began in 2020. The future Improved Warning and
SURGXFWLRQ GRVDJH IRUPV ZLOO KDYH W\SHV Monitoring Mechanism of
LQMHFWLRQV WDEOHWV RUDO OLTXLGV FDSVXOHV DQG Drug Abuse
SDWFKHV DQG SURGXFWV PDGH LQ KRXVH LQ
order to continuously improve the in-house Introduction of the Policy
manufacturing capability and production
capacity. New Psychoactive Substances (NPS)
have a wide range of varieties and have
In order to expand the storage area developed rapidly. In order to effectively
RI SURGXFWV DQG UDZ PDWHULDOV WKH ZKROH PRQLWRU WKH 136 7)'$ KDG UHLQIRUFHG RXU
plant project was started in June 2020. It approved institutions’ capabilities in urine
is expected that after completion of the WHVWLQJ RI LOOHJDO GUXJV DQG FROOHFWHG GUXJ
SURMHFW LW ZLOO SDVV WKH 3,& 6 *03 DQG abuse incidents reported through healthcare
*'3 FRPSOLDQFH DVVHVVPHQW DV VKRZQ LQ facilities and other statistics such as drug
Figure4-1 Injection production equipment Figure4-2 As-built drawings of the renovated plant
53
